Published in Blood Weekly, May 1st, 2008
"In a two-center, randomized, double-blind, comparative trial, 90 healthy postmenopausal women (aged 56.6 +/- 4.7 y) received daily continuous combined hormone therapy, either E-2/NET 175 mu g/275 mu g intranasally as a spray (n = 47) or E-2/NET acetate 1 mg/0.5 mg orally as a capsule (n = 43) for 1...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.